Disease Category
Allergic Diseases
Synonyms
Atopic Dermatitis

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

The primary safety objective of this study is to compare the safety profile of ShA9 to placebo (vehicle) over 14 weeks of application, which includes an initial two-week period of co-treatment with topical corticosteroids (TCS).

Contact Information

Office/Contact: Alexandra Fernandez-Desoto
Phone: 858-657-8390
Email: alf013@health.ucsd.edu
 

Topical Steroid Withdrawal Diagnostic Criteria Defined by NIH Researchers

Topical steroid withdrawal (TSW) results in dermatitis that is distinct from eczema and is caused by an excess of NAD+, an essential chemical compound in the body, according to a new study from NIAID researchers.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Seal, Stopping Eczema and Allergy Study

The objective of this study is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).

Contact Information

Office/Contact: SNP Center Inquiry
Phone: 650-521-7237
Email: snpcenterallergy_inquiry@stanford.edu
 

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

To create a repository of clinical, laboratory, and diagnostic data and specimens from a cohort of suspected or confirmed atopic or allergic individuals with diverse disorders seen by allergist-immunologists and rhinologists.

Contact Information

Office/Contact: NIH Clinical Center Office of Patient Recruitment (OPR)
Phone: 800-411-1222
TTY: TTY dial 711
Email: ccopr@nih.gov
 

Eczema Prevention Research

Currently there is no clearly effective way to prevent eczema. Many studies have tested a variety of eczema prevention strategies in pregnant and breastfeeding women and in infants. These include emollients or moisturizers, probiotics, prebiotics, synbiotics, vitamin D supplementation, hydrolyzed baby formula, early introduction of egg or cow’s milk, dietary supplements during breastfeeding, dust mite avoidance, Bacillus Calmette-Guerin (BCG) vaccination, antimicrobials, anti-worm medications, and antibiotic avoidance. Of all these experimental interventions, only a few have led to a small or modest reduction in the risk for childhood eczema.

Systems Biology of Early Atopy

The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions.

Contact Information

Office/Contact: Cassandra Thomas
Phone: 501-364-5178
Email: ThomasC1@archildrens.org
 

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.

Contact Information

Office/Contact: Amparito Cunningham
Phone: 857-218-5336
Email: asthma@childrens.harvard.edu
 

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment.

Contact Information

Office/Contact: Alexandra Fernandez-Desoto
Phone: 760-234-6428
Email: alf013@health.ucsd.edu
 

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

The purpose of this study is to learn about how the immune system and skin healing are related to each other.

Contact Information

Office/Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
Phone: 800-411-1222
TTY: TTY8664111010
Email: prpl@cc.nih.gov
 

Cardamom and Topical Roseomonas in Atopic Dermatitis

The objective of this study is to test a skin treatment that contains Roseomonas mucosa and ground cardamom seeds in people with atopic dermatitis (AD).

Contact Information

Office/Contact: NIH Clinical Center Office of Patient Recruitment (OPR)
Phone: 800-411-1222
TTY: TTY dial 711
Email: ccopr@nih.gov
 

Subscribe to Eczema (Atopic Dermatitis)